acquired
Stage
About
Psyadon Pharmaceuticals developed ecopipam, a dopamine D-1 antagonist, intended for the treatment of Tourette's syndrome, a neurological disorder characterized by motor and phonic tics.
Explore Psyadon Pharmaceuticals's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.